This site is intended for healthcare professionals residing in Canada.

Visit Pfizer AcademySearch

Menu

Close

Sign InLog Out
  • EN
ProductsTherapy AreasExplore ContentExplore
ContentGo to Explore ContentEventsMaterialsVideosPatient SupportContact
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Français

Menu

Close

About Prevnar 20About Prevnar 2020 SerotypesMechanism of actionImmunogenicity profileSafety profileDosing and administrationDosing and administrationDosingAdministrationInvasive pneumococcal diseaseInvasive pneumococcal diseaseDisease burden in infants and childrenSerotype distributionGuidelinesResourcesResourcesMaterialsVideos
Safety InformationProduct MonographPrevnar 20 Adult
Canadian GuidelinesPrevnar 20 is now recommended by NACI for routine pediatric immunization programs1,2Prevnar 20: Recognized by NACI for children less than 5 years old1,2

Prevnar 20 is currently recommended by NACI for routine pediatric immunization programs of healthy infants to help prevent IPD due to serotypes contained in the vaccine.1

Prevnar 20 should be provided using either a 3-dose (2+1) schedule at 2, 4 and 12 months of age, or a 4-dose (3+1) schedule at 2, 4 and 6 months followed by a dose at 12 to 15 months of age.1‑3*

Prevnar 20 is the NACI recommended choice for infants at high risk of IPD1*
  • Infants at increased risk of IPD should be immunized with Prevnar 20 vaccine using a 4‑dose schedule at 2 months, 4 months, 6 months and a dose at 12 to 15 months of age.

Visit the NACI website for the most current recommendations.

 Canada’s vaccination coverage goal by 2025

As part of the National Immunization Strategy objectives for 2016-2021, a vaccination coverage goal of 95% has been established for all childhood vaccines by two and seven years of age, to help prevent diseases such as pneumococcal disease through routine vaccination.4

IPD: Invasive pneumococcal disease; NACI: National Advisory Committee on Immunization

* Please see the Product Monograph and Canadian Immunization Guidelines for complete recommendations.

References:An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI). Recommendations for public health programs on the use of pneumococcal vaccines in children, including the use of 15-valent and 20-valent conjugate vaccines. Available at: https://www.canada.ca/content/dam/phac-aspc/documents/services/publications/vaccines-immunization/national-advisory-committee-immunization-recommendations-public-health-programs-use-pneumococcal-vaccines-children-including-use-15-valent-20-valent-conjugate-vaccines/naci-statement-2024-03-11.pdf. Accessed March 20, 2024.Health Canada. Canadian Immunization Guide Part 4 – Active Vaccines: Pneumococcal Vaccines. Available at: https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-16-pneumococcal-vaccine.html#a7. Accessed March 20, 2024.Public Health Agency of Canada. Provincial and territorial routine and catch-up vaccination schedule for infants and children in Canada. Available at: https://www.canada.ca/en/public-health/services/provincial-territorial-immunization-information/provincial-territorial-routine-vaccination-programs-infants-children.html. Accessed February 22, 2024.Public Health Agency of Canada. Vaccination Coverage Goals and Vaccine Preventable Disease Reduction Targets by 2025. Available at: https://www.canada.ca/en/public-health/services/immunization-vaccine-priorities/national-immunization-strategy/vaccination-coverage-goals-vaccine-preventable-diseases-reduction-targets-2025.html. Accessed September 18, 2023. NEXT

Resources

 Visit page Loading EXPLORE MORE

Dosing

 Visit page Loading
PP-PNR-CAN-0106-EN

To report an adverse event, please call 1-866-723-7111

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign Out

© Pfizer Canada ULC 2024. All rights reserved. The information is intended only for healthcare professionals resident in Canada. ®Pfizer Inc., used under license.

PP-UNP-CAN-0145-EN
You are now leaving Pfizerpro.ca website
Links to other sites are provided as a convenience to the viewer, and should not be taken as an endorsement of the sites or an association with their owners. Pfizer Canada accepts no responsibility for the content of linked sites.
You are now leaving the PfizerPro Portal.
You are about to view resources made available by Pfizer Academy. 
These resources include learning programs and upcoming events. By selecting Go to link below, you acknowledge and certify that you are a Canadian Healthcare Professional.
PP-UNP-CAN-0013 EN